Author Archives: Marisa Wexler MS

Rinvoq Approved in EU for Two Types of Active Arthritis

AbbVie‘s Rinvoq (upadacitinib) has been approved in the European Union to treat active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy. The European Commission also approved Rinvoq to treat active psoriatic arthritis (PsA) in adults who have not responded to, or are…

FDA Approves Generic Version of Celebrex

The U.S. Food and Drug Administration (FDA) has approved a generic version of Pfizer‘s Celebrex (celecoxib), an oral medication used to treat inflammation and pain caused by ankylosing spondylitis and other disorders. The new generic is made by the India-based company Unichem Laboratories, which announced the approval…

Clinical Trial Data Show Durable Efficacy of Cimzia, Bimekizumab

Treatment with Cimzia (certolizumab pegol) can ease eye inflammation in people with ankylosing spondylitis (AS), and reduce symptoms in those with active non-radiographic axial spondyloarthritis (nr-axSpA), new clinical trial data show. The data were presented by researchers from UCB — which markets Cimzia — and other institutions at…

Xeljanz Eases AS Symptoms in Phase 3 Trial

Treatment with Xeljanz (tofacitinib) was found to significantly ease symptoms of ankylosing spondylitis (AS) in a Phase 3 clinical trial. The results are being presented today at ACR Convergence 2020, in a session titled “Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis…

AS Pain Linked With Depression, Anxiety, Stress, Study Finds

People with ankylosing spondylitis (AS) often endure considerable psychological distress — including depression, anxiety, and stress — that is related to their experience of pain, a study shows. These findings highlight a need for more mental health resources for people with this disorder, the researchers said. The study, “…